Value-critical regulatory, portfolio, and governance decisions across biopharma environments. Influencing asset value, partnering readiness, and development risk.

Advising biopharma companies, investors, and leadership teams on development, regulatory, and governance decisions that directly impact asset value, development risk, timelines, and partnering readiness. This includes regulatory pathway strategy, portfolio prioritisation, development sequencing, partnering and licensing readiness, due diligence support, and cross-functional governance across complex biopharma environments.

Strategic sparring for boards, CEOs, founders, and investors navigating complexity and governance risk.

Independent strategic advisory for boards, non-executive directors, founders, and C-suite leaders navigating high-stakes decisions in regulated biopharma environments. This includes board-level regulatory risk oversight, governance support, and strategic review of development and portfolio decisions, as well as advisory across M&A, licensing, fundraising, partnering, and due diligence situations.

Supporting leadership teams in accelerating complex development and strategic decision-making under uncertainty through integrated regulatory, CMC, (non-)clinical, and development strategy for high-impact asset decisions.

Cross-functional advisory spanning regulatory strategy, (non-)clinical development planning, HTA and market access considerations, safety strategy, and manufacturing alignment. Designed for companies navigating integrated development decisions where regulatory, CMC, (non-)clinical, HTA and commercial considerations intersect, from early programme design through to filing strategy and post-authorisation planning. Supporting leadership teams in accelerating complex development and strategic decision-making under uncertainty.